What are the indications for enoxaparin (low molecular weight heparin) in cardiac conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cardiac Indications for Enoxaparin

Enoxaparin is indicated in cardiac conditions primarily for acute coronary syndromes (both NSTE-ACS and STEMI), where it serves as anticoagulation during initial medical management and as bridging therapy to revascularization procedures.

Primary Cardiac Indications

1. Non-ST Elevation Acute Coronary Syndromes (NSTE-ACS)

Enoxaparin is indicated for unstable angina and non-ST elevation myocardial infarction 1. The evidence demonstrates:

  • Superior efficacy to unfractionated heparin in reducing death, MI, and recurrent ischemia both short-term and up to 1 year 2, 3
  • Effective when combined with dual antiplatelet therapy and glycoprotein IIb/IIIa inhibitors 2
  • Works well in both conservative and early invasive strategies 3

Dosing for NSTE-ACS: 1 mg/kg subcutaneous every 12 hours 1

Key caveat: While enoxaparin shows superior efficacy, this benefit must be balanced against a modest increase in bleeding complications, particularly in the current era of early revascularization 3.

2. ST-Elevation Myocardial Infarction (STEMI)

Enoxaparin is indicated as adjunctive anticoagulation in STEMI patients, particularly those receiving fibrinolytic therapy 1, 4.

Dosing varies by age and renal function 1:

  • Age <75 years: 30 mg IV bolus, followed in 15 minutes by 1 mg/kg subcutaneous every 12 hours (maximum 100 mg for first 2 doses)
  • Age ≥75 years: No bolus; 0.75 mg/kg subcutaneous every 12 hours (maximum 75 mg for first 2 doses)
  • CrCl <30 mL/min (any age): 1 mg/kg subcutaneous every 24 hours

The ExTRACT-TIMI 25 trial demonstrated that enoxaparin significantly reduced the 30-day composite of all-cause mortality plus recurrent nonfatal MI compared to UFH in STEMI patients receiving fibrinolysis 4. This benefit persisted at 1-year follow-up, though bleeding was more frequent with enoxaparin 4.

3. Bridging Anticoagulation to Revascularization

For patients with ACS undergoing coronary revascularization (PCI or CABG), parenteral anticoagulation with enoxaparin is indicated until the procedure 1.

Critical pitfall: Premature discontinuation of anticoagulation causes rebound thrombin activity with greatest reinfarction risk in the first 4-8 hours 1.

Transition to PCI: When patients transition from medical management to the catheterization laboratory, dosing schedules based on timing of last enoxaparin dose ensure adequate anticoagulation 5.

Important Clinical Considerations

Advantages Over Unfractionated Heparin

  • Predictable pharmacokinetics allowing fixed dosing without monitoring 3, 6
  • Greater bioavailability and more stable anticoagulation 3
  • Lower incidence of heparin-induced thrombocytopenia 3
  • Subcutaneous administration versus continuous IV infusion 6

Safety Profile

While major bleeding rates are generally similar to UFH during acute phases, minor bleeding is consistently higher with enoxaparin 6. The elderly (≥75 years) require dose reduction due to increased bleeding risk 1, 4.

Renal Dosing is Critical

Enoxaparin accumulates in renal insufficiency. Dose adjustment to every 24 hours is mandatory when CrCl <30 mL/min 1.

Not a Class Effect

The evidence supporting enoxaparin does not extend to all low-molecular-weight heparins 2, 7. Each LMWH has unique chemical, pharmacological, and clinical profiles—they are not interchangeable 7.

Duration of Therapy

Enoxaparin is typically continued for up to 8 days or until revascularization, whichever comes first 4. For patients with ACS, anticoagulation should not be prematurely discontinued before definitive management 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.